Hopkinson Craig C.
EVP R&D, Chief Medical Officer at ALKS
- Sold, on record
- $24.7M
- Dollars the filings state
- Form 4 sales
- 25
- Latest Sep 1, 2026
- Form 144 notices
- 15
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- ALKSAlkermes plc.EVP R&D, Chief Medical Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 144 notice ALKSNoticeFeb 2, 2026 2026
Filed to sell 9,000 shares ($305k)
Hopkinson Craig C., Officer
10b5-1 plan1x usual sizeFiling
- 2 Form 4 sale ALKSRoutineMar 2, 2026 +28 days
Sold 9,000 shares at $29.72 ($267k)
Hopkinson Craig C., EVP R&D, Chief Medical Officer
10b5-1 planSold 9.1% of holdings ($2.9M position)89,389 shares left1x usual sizeFiling
- 3 Form 4 sale ALKSRoutineApr 1, 2026 +30 days
Sold 9,000 shares at $35.51 ($320k)
Hopkinson Craig C., EVP R&D, Chief Medical Officer
10b5-1 planSold 9.5% of holdings ($3.4M position)85,389 shares left1x usual sizeFiling
- 4 Form 4 sale ALKSRoutineMay 1, 2026 +30 days
Sold 9,000 shares at $33.40 ($301k)
Hopkinson Craig C., EVP R&D, Chief Medical Officer
10b5-1 planSold 10% of holdings ($3M position)81,389 shares left1x usual sizeFiling
- 5 Form 4 sale ALKSRoutineJun 1, 2026 +31 days
Sold 9,000 shares at $41.67 ($375k)
Hopkinson Craig C., EVP R&D, Chief Medical Officer
10b5-1 planSold 10.4% of holdings ($3.6M position)77,389 shares left1x usual sizeFiling
- 6 Form 4 sale ALKSRoutineJul 1, 2026 +30 days
Sold 9,000 shares at $51.51 ($464k)
Hopkinson Craig C., EVP R&D, Chief Medical Officer
10b5-1 planSold 10.9% of holdings ($4.2M position)73,389 shares left1x usual sizeFiling
- 7 Form 4 sale ALKSRoutineAug 3, 2026 +33 days
Sold 9,000 shares at $48.58 ($437k)
Hopkinson Craig C., EVP R&D, Chief Medical Officer
10b5-1 planSold 11.5% of holdings ($3.8M position)69,389 shares left1x usual sizeFiling
- 8 Form 4 sale ALKSRoutineSep 1, 2026 +29 days
Sold 9,000 shares at $46.99 ($423k)
Hopkinson Craig C., EVP R&D, Chief Medical Officer
10b5-1 planSold 12.1% of holdings ($3.5M position)65,389 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (40)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Sep 1, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $423k | 12.1% | Routine | SEC |
| Aug 3, 2026 | Aug 3, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $437k | 11.5% | Routine | SEC |
| Jul 1, 2026 | Jul 1, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $464k | 10.9% | Routine | SEC |
| Jun 1, 2026 | Jun 1, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $375k | 10.4% | Routine | SEC |
| May 1, 2026 | May 1, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $301k | 10.0% | Routine | SEC |
| Apr 1, 2026 | Apr 1, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $320k | 9.5% | Routine | SEC |
| Mar 2, 2026 | Mar 4, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $267k | 9.1% | Routine | SEC |
| Feb 2, 2026 | Feb 2, 2026 | ALKS | Officer | Form 144 notice | 9,000 | $305k | Notice | SEC | |
| Feb 2, 2026 | Feb 2, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $305k | 13.5% | Routine | SEC |
| Jan 8, 2026 | Jan 8, 2026 | ALKS | Officer | Form 144 notice | 5,000 | $150k | Notice | SEC | |
| Jan 8, 2026 | Jan 8, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 5,000 | $150k | 7.5% | Routine | SEC |
| Jan 2, 2026 | Jan 2, 2026 | ALKS | Officer | Form 144 notice | 4,000 | $112k | Notice | SEC | |
| Jan 2, 2026 | Jan 2, 2026 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 4,000 | $112k | 6.1% | Routine | SEC |
| Dec 3, 2025 | Dec 5, 2025 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 3,748 | $112k | 5.4% | Routine | SEC |
| Dec 3, 2025 | Dec 3, 2025 | ALKS | Officer | Form 144 notice | 3,748 | $112k | Notice | SEC | |
| Dec 1, 2025 | Dec 1, 2025 | ALKS | Officer | Form 144 notice | 4,000 | $117k | Notice | SEC | |
| Dec 1, 2025 | Dec 1, 2025 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 4,000 | $117k | 5.7% | Routine | SEC |
| Nov 3, 2025 | Nov 3, 2025 | ALKS | Officer | Form 144 notice | 9,000 | $273k | Notice | SEC | |
| Nov 3, 2025 | Nov 3, 2025 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $273k | 11.4% | Routine | SEC |
| Oct 15, 2025 | Oct 15, 2025 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,000 | $284k | 10.9% | Routine | SEC |
| Oct 15, 2025 | Oct 15, 2025 | ALKS | Officer | Form 144 notice | 9,000 | $284k | Notice | SEC | |
| Feb 13, 2025 | Feb 14, 2025 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 349,340 | $11.8M | 85.8% | Unusual | SEC |
| Feb 13, 2025 | Feb 13, 2025 | ALKS | Officer | Form 144 notice | 144,419 | $5.1M | Notice | SEC | |
| Feb 12, 2025 | Feb 12, 2025 | ALKS | Officer | Form 144 notice | 204,921 | $6.7M | Notice | SEC | |
| Jan 30, 2025 | Jan 31, 2025 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 100,918 | $3.2M | 69.5% | Unusual | SEC |
| Jan 30, 2025 | Jan 30, 2025 | ALKS | Officer | Form 144 notice | 100,918 | $3.2M | Notice | SEC | |
| Dec 9, 2024 | Dec 9, 2024 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 61,151 | $2M | 56.2% | Routine | SEC |
| Dec 9, 2024 | Dec 9, 2024 | ALKS | Officer | Form 144 notice | 61,151 | $2M | Notice | SEC | |
| Dec 5, 2024 | Dec 5, 2024 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 9,221 | $290k | 13.4% | Routine | SEC |
| Dec 5, 2024 | Dec 5, 2024 | ALKS | Officer | Form 144 notice | 9,221 | $290k | Notice | SEC | |
| Dec 4, 2024 | Dec 4, 2024 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 14,349 | $442k | 17.2% | Routine | SEC |
| Dec 4, 2024 | Dec 4, 2024 | ALKS | Officer | Form 144 notice | 14,349 | $442k | Notice | SEC | |
| Nov 11, 2024 | Nov 12, 2024 | ALKS | Officer | Form 144 notice | 58,996 | $1.8M | Notice | SEC | |
| Nov 11, 2024 | Nov 12, 2024 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 58,996 | $1.8M | 41.5% | Routine | SEC |
| Nov 6, 2024 | Nov 6, 2024 | ALKS | Officer | Form 144 notice | 10,471 | $309k | Notice | SEC | |
| Nov 6, 2024 | Nov 6, 2024 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 10,471 | $309k | 9.5% | Routine | SEC |
| Feb 23, 2022 | Feb 24, 2022 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 11,983 | $297k | 40.0% | Unusual | SEC |
| Feb 18, 2022 | Feb 23, 2022 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 2,306 | $58k | 19.5% | Plan not stated | SEC |
| Jun 9, 2021 | Jun 11, 2021 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 882 | $22k | 100.0% | Unusual | SEC |
| Apr 15, 2021 | Apr 16, 2021 | ALKS | EVP R&D, Chief Medical Officer | Form 4 sale | 28,920 | $570k | 100.0% | Unusual | SEC |